Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya H Buch

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Annals of the Rheumatic Diseases|August 19, 2018
Response to 'Correspondence to viewpoint 'Defining refractory rheumatoid arthritis' by Buch' by Roodenrijs <i>et al</i>Maya H Buch
Current Opinion in Rheumatology|March 2, 2010
Sequential use of biologic therapy in rheumatoid arthritisMaya H Buch
Annals of the Rheumatic Diseases|March 29, 2018
Defining refractory rheumatoid arthritisMaya H Buch
Seminars in Arthritis and Rheumatism|December 21, 2023
What is Surveillance teaching us (and what it is not?)Maya H Buch
Rheumatology (Oxford, England)|April 5, 2026
Primary myocardial involvement in systemic sclerosis: pathophysiology, clinical manifestations, and advances in cardiac imagingMaya H Buch
RMD Open|November 12, 2025
Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritisGyörgy Nagy, Maya H Buch
Current Opinion in Rheumatology|March 24, 2011
New therapies in the management of rheumatoid arthritisMaya H Buch, Paul Emery
Nature Clinical Practice. Rheumatology|August 26, 2006
Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?Maya H Buch, Paul Emery
Lancet (London, England)|April 3, 2012
Towards an optimum strategy in rheumatoid arthritisPaul Emery, Maya H Buch
Annals of the Rheumatic Diseases|February 9, 2021
Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis <i>et al</i>Sven Plein, Maya H Buch
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|August 19, 2018
Response to 'Correspondence to viewpoint 'Defining refractory rheumatoid arthritis' by Buch' by Roodenrijs <i>et al</i>Maya H Buch
Current Opinion in Rheumatology|March 2, 2010
Sequential use of biologic therapy in rheumatoid arthritisMaya H Buch
Annals of the Rheumatic Diseases|March 29, 2018
Defining refractory rheumatoid arthritisMaya H Buch
Seminars in Arthritis and Rheumatism|December 21, 2023
What is Surveillance teaching us (and what it is not?)Maya H Buch
Rheumatology (Oxford, England)|April 5, 2026
Primary myocardial involvement in systemic sclerosis: pathophysiology, clinical manifestations, and advances in cardiac imagingMaya H Buch
RMD Open|November 12, 2025
Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritisGyörgy Nagy, Maya H Buch
Current Opinion in Rheumatology|March 24, 2011
New therapies in the management of rheumatoid arthritisMaya H Buch, Paul Emery
Nature Clinical Practice. Rheumatology|August 26, 2006
Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?Maya H Buch, Paul Emery
Lancet (London, England)|April 3, 2012
Towards an optimum strategy in rheumatoid arthritisPaul Emery, Maya H Buch
Annals of the Rheumatic Diseases|February 9, 2021
Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis <i>et al</i>Sven Plein, Maya H Buch
Pageof 18